We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

29 hedge funds and large institutions have $151K invested in Aspire Biopharma Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 29 → 29 (0)

3.2% less ownership

Funds ownership: 30.92% → 27.71% (-3.2%)

46% less capital invested

Capital invested by funds: $277K → $151K (-$127K)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
29
Holders Change
–
Holders Change %
0%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
1
Reduced
4
Closed
–
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$342
2
FTUS
Flow Traders U.S.
New York
+$10

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$6.96K
2
Verition Fund Management
Verition Fund Management
Connecticut
-$4.93K
3
CS
Clear Street
New York
-$2
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$2
Name Holding Trade Value Shares
Change 		Change in
Stake
MTCM
1
Mint Tower Capital Management
Netherlands
$26K – – –
SCM
2
Saba Capital Management
New York
$17.9K – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$17.4K – – –
LA
4
Linden Advisors
New York
$16.9K – – –
AC
5
Aristeia Capital
Connecticut
$12.4K – – –
SC
6
Sculptor Capital
New York
$9.1K – – –
Toronto Dominion Bank
7
Toronto Dominion Bank
Ontario, Canada
$8.78K -$2 -100 -0%
CS
8
Clear Street
New York
$5.49K -$2 -100 -0%
HCM
9
Highbridge Capital Management
New York
$4.01K – – –
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$3.32K – – –
WAM
11
Wolverine Asset Management
Illinois
$3.27K – – –
Verition Fund Management
12
Verition Fund Management
Connecticut
$3.17K -$4.93K -241,736 -56%
CCM
13
Context Capital Management
California
$2.9K – – –
CA
14
Crossingbridge Advisors
New York
$2.79K – – –
PAMP
15
Polar Asset Management Partners
Ontario, Canada
$2.52K – – –
LP
16
LMR Partners
United Kingdom
$2.08K – – –
PC
17
Periscope Capital
Ontario, Canada
$2.07K – – –
WA
18
Whitebox Advisors
Minnesota
$1.97K – – –
VAS
19
VR Advisory Services
Cayman Islands
$1.66K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$1.47K – – –
LIA
21
Limestone Investment Advisors
New York
$1.25K – – –
AC
22
Athos Capital
Hong Kong
$1K – – –
BOCH
23
Blue Owl Capital Holdings
New York
$1K – – –
PMAM
24
Picton Mahoney Asset Management
Ontario, Canada
$830 – – –
OAC
25
OMERS Administration Corp
Ontario, Canada
$415 – – –
1
2

ASBPW Hedge Fund Activity: Q1 2026 in Review

29 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2026, worth a combined $151K — down 46% from $277K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ASBPW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $342. The largest seller was Barclays, cutting an estimated $6.96K.

  • 29 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $151K of Aspire Biopharma Warrant stock for Q1 2026, down 46% quarter-over-quarter.
  • 1 fund opened new Aspire Biopharma Warrant positions in Q1 2026 and 0 closed out, a net change of +1 holder.
  • The largest Aspire Biopharma Warrant buyer in Q1 2026 was Susquehanna International Group, an estimated $342 added.
  • The largest Aspire Biopharma Warrant seller in Q1 2026 was Barclays, an estimated $6.96K sold.

Based on aggregated 13F filings for Q1 2026.